Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      NeoGenomics Reports 27% Revenue Growth Driven by Strong Volume Gains and PathLogic Acquisition


      News provided by

      NeoGenomics, Inc.

      Apr 28, 2015, 07:00 ET

      Share this article

      Share this article


      FT. MYERS, Fla., April 28, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2015.

      First Quarter 2015 Highlights:

      • Consolidated revenue growth of 27%
      • Base(1) test volume growth of 28%
      • Improvement in base average cost per test of 3.5%
      • Adjusted EBITDA(2) of $1.5 million

      Revenue for the first quarter was $23.0 million, a 27% increase over first quarter 2014 revenue.  The PathLogic acquisition accounted for $2.3 million of revenue or 13% of this revenue growth, and organic revenue growth in the base(1) business, excluding PathLogic, was 14%.  Base testing volume growth was 28% and average revenue per test decreased by 11%, primarily as a result of significant decreases in reimbursement for Fluorescence in-situ Hybridization ("FISH") testing.

      Consolidated gross margin was 41.5% compared to 47.9% in last year's first quarter.  Base business gross margin declined to 43.7% from 47.9% in last year's first quarter, primarily as a result of the decreases in reimbursement for FISH testing.  Gross margin at PathLogic was 22.0% for the quarter.  Consolidated operating expenses increased by $1.8 million or 22% from Quarter 1 of last year.  About half of this increase was the result of the PathLogic acquisition.  The remainder was due to increased sales and marketing personnel and increases in Information Technology and facilities expense to accommodate recent and near-term growth prospects.     

      Net loss was $761,000 or ($0.01)/share versus net income of $102,000 or $0.00/share in Quarter 1 of last year.  Consolidated Adjusted EBITDA(1) for the quarter was $1.5 million, a 9.8% decrease from last year, due primarily to decreases in reimbursement and the incorporation of PathLogic's results.  Adjusted EBITDA(2) from the base business and PathLogic were $1.8 million and ($246,000), respectively.        

      Douglas M. VanOort, the Company's Chairman and CEO, commented, "NeoGenomics base business test volume, service levels, and new account activities were very strong in the first quarter.  We continue to make excellent market-share gains in our base business where test volumes grew by 28% compared to last year's first quarter.  Unusually harsh winter in the northern part of the country also impacted growth somewhat in January and February." 

      "We are particularly pleased with the excellent progress we are making on our many growth initiatives.  Our volume of molecular testing, fueled by Next Generation Sequencing, increased by about 52% over last year and now is our largest testing category by volume.  Our approach to molecular testing of using targeted profiles by disease category is becoming more widely accepted as a cost effective way to identify the key genetic drivers of cancer.  Momentum was also strong in clinical trials testing.  In fact, we were awarded more studies in the first quarter than in all of last year."

      Mr. VanOort continued, "We are disappointed, however, by the extraordinary reduction in reimbursement rates for FISH testing by Medicare and commercial insurers.  FISH testing is critically important for proper diagnosis and treatment for cancer patients.  Unfortunately, we believe that Medicare reimbursement rates for the new 2015 FISH CPT Codes were not properly established and commercial insurance payers used these as benchmarks for their own reimbursement policies.  We estimate that declines in FISH reimbursement reduced our revenue by approximately $2.1 million in Quarter 1, and most of that amount similarly reduced profit.  Fortunately, some large commercial insurers have analyzed the rates and are now in the process of revising their FISH reimbursement upward.  We are working hard to explain to all payers that adequate reimbursement for FISH testing is of critical importance to ensure that cancer patients are properly diagnosed and treated." 

      Mr. VanOort concluded, "Our genetic and molecular testing business is strong, and we continue to attract new customers with our comprehensive testing menu and service levels.  We believe that volume growth and process and productivity improvements will allow for a return to profitability in the second half of this year.  We remain committed to invest in growth through innovation as we continue to develop and commercialize new and innovative tests.  In this environment, we believe that acquisition opportunities are available and we remain active and disciplined in our approach to evaluating them.  Overall, we are excited about the many prospects for our company." 

      Full-Year 2015 Financial Outlook:

      The Company reiterated its previously issued revenue guidance for the full year 2015 of $103 - $108 million.  Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.  

      (1)  PathLogic was acquired by NeoGenomics on July 8, 2014.  To facilitate year-over-year comparisons, base NeoGenomics figures exclude the impact from the consolidation of PathLogic.

      (2)  Adjusted EBITDA is defined as earnings before interest, taxes, depreciation, amortization, and non-cash stock-based compensation expenses.  See table for a reconciliation to net income.

      Conference Call

      The Company has scheduled a web-cast and conference call to discuss their Q1 2015 results on Tuesday, April 28, 2015 at 11:00 AM EDT.  Interested investors should dial (877) 407-0782 (domestic) and (201) 689-8567 (international) at least five minutes prior to the call and ask for Conference ID Number 13607040.  A replay of the conference call will be available until 11:59 PM on May 12, 2015 and can be accessed by dialing (877) 660-6853 (domestic) and (201) 612-7415 (international).  The playback conference ID Number is 13607040.  The web-cast may be accessed under the Investor Relations section of our website at www.neogenomics.com or http://www.investorcalendar.com/IC/CEPage.asp?ID=173918.  An archive of the web-cast will be available until 11:59 PM on July 28, 2015.

      About NeoGenomics, Inc.

      NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.  The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. 

      Headquartered in Fort Myers, FL, NeoGenomics has laboratories in Nashville, TN, Irvine, Fresno and West Sacramento CA, Tampa and Fort Myers, FL.  NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.    

      Interested parties can also access investor relations material from Hawk Associates at http://www.hawkassociates.com or [email protected].

      Forward Looking Statements

      Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements.  These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements.  Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.


      NeoGenomics, Inc.


      CONDENSED CONSOLIDATED BALANCE SHEETS
      (Unaudited, in thousands)











      ASSETS


      March 31,

      2015


      December 31,

      2014











        Cash, cash equivalents

      $

      31,248

      $

      33,689






        Accounts Receivable (net of allowance for doubtful

           accounts of $4,079 and $4,180, respectively)


      21,484


      20,475






        Other Current Assets


      4,599


      4,578






      TOTAL CURRENT ASSETS


      57,331


      58,742






      PROPERTY AND EQUIPMENT (net of accumulated

         depreciation of $21,406 and $19,822, respectively)


      16,640


      15,082






      INTANGIBLE ASSETS (net of accumulated amortization of $793 and $700, respectively)


      4,119


      4,212

      GOODWILL


      2,929


      2,929

      OTHER ASSETS


      139


      141






          TOTAL

      $

      81,158

      $

      81,106






      LIABILITIES AND STOCKHOLDERS' EQUITY










      CURRENT LIABILITIES

      $

      13,855

      $

      14,623






      LONG TERM LIABILITIES


      7,148


      6,078






          TOTAL LIABILITIES


      21,003


      20,701






      STOCKHOLDERS' EQUITY


      60,155


      60,405






         TOTAL

      $

      81,158

      $

      81,106







      NeoGenomics, Inc.


      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
      (Unaudited, in thousands, except per share data)





      For the

      Three
      Months

      Ended

       March 31,
      2015


      For the

      Three
      Months

      Ended

      March 31,
      2014






      REVENUE

      $

      23,026

      $

      18,182






      COST OF REVENUE


      13,482


      9,473






      GROSS PROFIT


      9,544


      8,709






      OPERATING EXPENSES:





      General and administrative


      6,522


      5,054

      Research and development


      669


      628

      Sales and marketing


      2,914


      2,633

        Total operating expenses


      10,105


      8,315






      INCOME (LOSS) FROM OPERATIONS


      (561)


      394






      INTEREST AND OTHER INCOME (EXPENSE) - NET


      (195)


      (265)






      INCOME (LOSS) BEFORE INCOME TAXES


      (756)


      129






      INCOME TAXES


      5


      27






      NET INCOME (LOSS)

      $

      (761)

      $

      102






      NET INCOME (LOSS) PER SHARE 





      - Basic

      $

      (0.01)

      $

      0.00

      - Diluted

      $

      (0.01)

      $

      0.00






      WEIGHTED AVERAGE NUMBER

         OF SHARES OUTSTANDING –

      - Basic


      60,277


      49,277

      - Diluted


      60,277


      53,469







      NeoGenomics, Inc.






      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
      (Unaudited, in thousands)









      For the

      Three
      Months
      Ended

      March 31,
      2015


      For the

      Three
      Months
      Ended

      March 31,
      2014






      NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES

      $

      (787)

      $

      1,025






      NET CASH USED IN INVESTING ACTIVITIES


      (842)


      (883)






      NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES


      (812)


      409






                  NET INCREASE IN CASH AND CASH EQUIVALENTS


      (2,441)


      551






      CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD


      33,689


      4,834






      CASH AND CASH EQUIVALENTS, END OF PERIOD

      $

      31,248

      $

      5,385






      SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:










      Interest paid

      $

      212

      $

      254

      Income taxes paid

      $

      5

      $

      159






       SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND  FINANCING ACTIVITIES:






           Equipment leased under capital lease and equipment loans

      $

      2,525

      $

      1,693






      NeoGenomics, Inc.




      RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP EBITDA AND ADJUSTED EBITDA
      (Unaudited, in thousands)





      For the Three Months Ended
      March 31,



      2015


      2014






      Net income (loss)

      $

      (761)

      $

      102






      Adjustments to Net Income:





         Interest expense (income), net


      195


      265

         Amortization of intangibles


      93


      56

         Depreciation


      1,586


      1,151

         Income taxes


      5


      27

       EBITDA


      1,118


      1,601






      Further Adjustments to EBITDA:





         Non-cash stock-based compensation


      401


      84

       Adjusted EBITDA

      $

      1,519

      $

      1,685

      Non – GAAP Adjusted EBITDA Definition

      "Adjusted EBITDA" is defined by NeoGenomics as net income (loss) from continuing operations before (i) interest expense, (ii) tax expense, (iii) depreciation and amortization expense, (iv) non-cash stock-based compensation and warrant amortization expense and (v) other extraordinary or non-recurring charges.  NeoGenomics believes that Adjusted EBITDA provides a more consistent measurement of operating performance and trends across reporting periods by excluding these cash and non-cash items of expense not directly related to ongoing operations from income.  Adjusted EBITDA also assists investors in performing analysis that is consistent with financial models developed by research analysts. 

      Adjusted EBITDA as defined by NeoGenomics is not a measurement under GAAP and may differ from non-GAAP measures used by other companies.  There are limitations inherent in non-GAAP financial measures such as Adjusted EBITDA because they exclude a variety of charges and credits that are required to be included in a GAAP presentation, and do not therefore present the full measure of NeoGenomics recorded costs against its net revenue.  Accordingly, investors should consider non-GAAP results together with GAAP results in analyzing NeoGenomics financial performance.

      NeoGenomics, Inc.


      Supplemental Information on Customer Requisitions Received and Tests Performed
      (Unaudited, in thousands, except test and requisition data)



      NeoGenomics, Inc. excluding Path Logic

      ("Base Business")

      For the

      Three
      Months

      Ended

      March 31,
      2015

      For the

       Three
      Months

      Ended

      March 31,
      2014

      % Increase
      (Decrease)





      Requisitions Received

      31,377

      24,704

      27.0%

      Number of Tests Performed

      49,396

      38,734

      27.5%

      Avg. # of Tests / Requisition

      1.57

      1.57

      0.4%





      Total Testing Revenue

      $20,684

      $18,182

      13.8%

      Avg. Revenue/Requisition

      $ 659

      $ 736

      (10.4)%

      Avg. Revenue/Test

      $ 419

      $ 469

      (10.8)%





      Total Cost of Revenue

      $11,656

      $9,473

      23.1%

      Avg. Cost/Requisition

      $371

      $383

      (3.1)%

      Avg. Cost/Test

      $236

      $245

      (3.5)%





      Path Logic

      For the

      Three
      Months
      Ended

      March 31,
      2015







      Requisitions Rec'd (cases)

      16,661







      Total Testing Revenue

      $2,343



      Avg. Revenue /Requisition

      $141







      Total Cost of Revenue

      $1,827



      Avg. Cost/Requisition

      $110



      SOURCE NeoGenomics, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.